Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25344246 | 0.88 | POLB (0.54) | POLBNPSR1MAPTTHRBKLKB1 | |
| SCHEMBL4591947 | 0.82 | POLB (0.61) | POLBNPSR1MAPTTHRBKLKB1 | |
| SCHEMBL1240350 | 0.82 | MAPT (0.56) | POLBNPSR1MAPTTHRBKLKB1 | |
| SCHEMBL8378861 | 0.82 | POLB (0.54) | POLBNPSR1KLKB1LMNA | |
| SCHEMBL9752787 | 0.82 | POLB (0.63) | POLBNPSR1MAPTTHRBKLKB1 | |
| SCHEMBL28003373 | 0.80 | EGLN1 (0.61) | POLBNPSR1MAPTKLKB1LMNA | |
| SCHEMBL31464345 | 0.79 | POLB (0.43) | POLBNPSR1MAPTTHRBKLKB1 | |
| SCHEMBL19513374 | 0.79 | KLKB1 (0.43) | POLBNPSR1THRBKLKB1 | |
| SCHEMBL27336863 | 0.79 | DBH (0.52) | POLBNPSR1KLKB1LMNA | |
| SCHEMBL15331170 | 0.78 | KLKB1 (0.43) | POLBNPSR1MAPTKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | POLB 3201/4885NPSR1 1602/4885PIK3CD 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.